Literature DB >> 7591628

Retinoic acid in silicone and silicone-fluorosilicone copolymer oils in a rabbit model of proliferative vitreoretinopathy.

M Nakagawa1, M F Refojo, J F Marin, M Doi, F I Tolentino.   

Abstract

PURPOSE: The authors evaluated the effect of retinoic acid (RA) in silicone oil (SiO) and in silicone-fluorosilicone (SiFO) copolymer oil in a new rabbit model of proliferative vitreoretinopathy (PVR).
METHODS: To create the PVR model, three groups of rabbits were administered vitreous injections of approximately 100,000 homologous fibroblasts, 75,000 platelet-rich plasma (PRP), and fibroblasts + PRP, respectively. These rabbits were followed up ophthalmoscopically and histopathologically for as long as 2 months. Five additional groups of rabbits underwent gas-compression vitrectomy in one eye. Four days later, group 1 was administered intravitreous RA in SiFO (9 micrograms/ml) with approximately 150,000 fibroblasts and 70,000 PRP. Group 3 was administered the same amount of fibroblasts and PRP as group 1 with RA in SiO (9 micrograms/ml). Groups 2, 4, and 5 were administered the same amount of fibroblasts and PRP as groups 1 and 3 with 1 ml of SiFO, SiO, or balanced salt solution only, respectively. To evaluate RA toxicity, RA was injected in SiO (15 and 20 micrograms/ml) and RA in SiFO (10 micrograms/ml).
RESULTS: All eyes that were administered fibroblasts or PRP developed vitreous membranes, but those with PRP alone did not develop proliferative changes or retinal detachment; fibroblasts alone produced proliferative changes and retinal detachment after 2 to 3 weeks; fibroblasts + PRP produced similar changes within 3 days of injection. Retinoic acid (15 micrograms/ml) in SiO and RA (10 micrograms/ml) in SiFO was well tolerated. Retinal atrophic changes were found in eyes with 20 micrograms/ml RA in SiO. The retinal detachment rate was lower (P < 0.05) in the eyes that were administered fibroblasts + PRP and RA than in the controls. Significant differences were found in the degrees of PVR among the groups.
CONCLUSIONS: RA could be useful in PVR treated with SiO or for eyes treated intraoperatively with heavier-than-water SiFO when it is used as a short-term retinal tamponade.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7591628

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  15 in total

1.  Growth factors outside the PDGF family drive experimental PVR.

Authors:  Hetian Lei; Gisela Velez; Peter Hovland; Tatsuo Hirose; Debra Gilbertson; Andrius Kazlauskas
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-03-25       Impact factor: 4.799

2.  Pathological signaling via platelet-derived growth factor receptor {alpha} involves chronic activation of Akt and suppression of p53.

Authors:  Hetian Lei; Gisela Velez; Andrius Kazlauskas
Journal:  Mol Cell Biol       Date:  2011-02-28       Impact factor: 4.272

3.  Vascular endothelial growth factor acts primarily via platelet-derived growth factor receptor α to promote proliferative vitreoretinopathy.

Authors:  Steven Pennock; Luis J Haddock; Shizuo Mukai; Andrius Kazlauskas
Journal:  Am J Pathol       Date:  2014-09-26       Impact factor: 4.307

4.  N-acetylcysteine suppresses retinal detachment in an experimental model of proliferative vitreoretinopathy.

Authors:  Hetian Lei; Gisela Velez; Jing Cui; Arif Samad; David Maberley; Joanne Matsubara; Andrius Kazlauskas
Journal:  Am J Pathol       Date:  2010-05-20       Impact factor: 4.307

5.  A novel strategy to develop therapeutic approaches to prevent proliferative vitreoretinopathy.

Authors:  Steven Pennock; Marc-Andre Rheaume; Shizuo Mukai; Andrius Kazlauskas
Journal:  Am J Pathol       Date:  2011-10-28       Impact factor: 4.307

6.  Expression of PDGFRα is a determinant of the PVR potential of ARPE19 cells.

Authors:  Hetian Lei; Marc-André Rhéaume; Gisela Velez; Shizuo Mukai; Andrius Kazlauskas
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-08-24       Impact factor: 4.799

7.  Safety and feasibility of a novel intravitreal tamponade using a silicone oil/acetyl-salicylic acid suspension for proliferative vitreoretinopathy: first results of the Austrian Clinical Multicenter Study.

Authors:  Martina Theresa Kralinger; Ulrike Stolba; Michaela Velikay; Stefan Egger; Susanne Binder; Andreas Wedrich; Anton Haas; Jean-Marie Parel; Gerhard Franz Kieselbach
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-04-28       Impact factor: 3.117

8.  Ranibizumab is a potential prophylaxis for proliferative vitreoretinopathy, a nonangiogenic blinding disease.

Authors:  Steven Pennock; David Kim; Shizuo Mukai; Matthew Kuhnle; Dal W Chun; Joanne Matsubara; Jing Cui; Patrick Ma; David Maberley; Arif Samad; Robert J Van Geest; Sarit L Oberstein; Reinier O Schlingemann; Andrius Kazlauskas
Journal:  Am J Pathol       Date:  2013-04-09       Impact factor: 4.307

9.  Plasmin is the major protease responsible for processing PDGF-C in the vitreous of patients with proliferative vitreoretinopathy.

Authors:  Hetian Lei; Gisela Velez; Peter Hovland; Tatsuo Hirose; Andrius Kazlauskas
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-01       Impact factor: 4.799

10.  Growth factors outside of the platelet-derived growth factor (PDGF) family employ reactive oxygen species/Src family kinases to activate PDGF receptor alpha and thereby promote proliferation and survival of cells.

Authors:  Hetian Lei; Andrius Kazlauskas
Journal:  J Biol Chem       Date:  2009-01-06       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.